[144/A] HOOKIPA Pharma Inc. SEC Filing
HOOKIPA Pharma Inc. filed a Form 144/A reporting a proposed sale of 25,172 shares of common stock to be executed on 08/19/2025 through Maxim Group on the NASDAQ. The filing lists an aggregate market value of $20,155 for the shares and shows 9,789,622 shares outstanding.
The securities were acquired as restricted stock units on 07/22/2024 (amount: 54,347) and the notice states the intended payment is compensation. The filing also discloses a recent sale on 07/23/2025 of 29,176 shares for $26,911. The signer represents no undisclosed material adverse information about the issuer.
- Transparent filing of planned insider sale with broker, date, and amount disclosed
- Includes recent sale activity (29,176 shares on 07/23/2025 for $26,911), improving market transparency
- Acquisition method disclosed (Restricted Stock Units dated 07/22/2024) and payment nature (compensation)
- None.
Insights
TL;DR: Routine insider sale disclosure; size is small relative to shares outstanding and unlikely to be material to valuation.
The Form 144/A documents a planned sale of 25,172 common shares by a person who acquired 54,347 RSUs in July 2024. With 9.79 million shares outstanding, the proposed sale represents a small fraction of equity (<0.26%). The filing provides transaction timing, broker identity, and recent past sales, which supports market transparency. There is no earnings or operational data here to reassess company fundamentals.
TL;DR: Disclosure complies with Rule 144 reporting elements; includes the required representations and broker details.
The submission identifies the broker (Maxim Group), sale date, acquisition method (RSUs), and past three-month sale activity, satisfying key Form 144 requirements. The signer affirms absence of undisclosed material adverse information, and the filing flags the transaction as compensation-related. From a compliance perspective, the document appears complete for a Rule 144 notice; it does not raise immediate regulatory red flags based on the provided fields.